<DOC>
	<DOCNO>NCT00210652</DOCNO>
	<brief_summary>The purpose study evaluate safety preliminary effectiveness novel compound RWJ-333369 patient partial onset seizure currently treat 1 2 concomitant antiepileptic drug .</brief_summary>
	<brief_title>An Open-Label Extension Study Evaluate Safety Effectiveness RWJ 333369 Patients With Epilepsy</brief_title>
	<detailed_description>333369EPY2002 open-label extension study follow double-blind study 333369EPY2001 . In open label study 333369EPY2002 , physician patient know name assign study medication . In double blind study 333369EPY2001 , neither physician patient know name assign study medication . Patients complete double-blind treatment phase study 333369EPY2001 eligible enter open-label extension study patient transition blind period open-label period carisbamate ( also refer RWJ-333369 ) . RWJ-333369 new chemical compound anticonvulsant activity currently investigation treatment epilepsy . Patients elect enter open-label extension phase supply open-label carisbamate ( RWJ-333369 ) blind study medication transition phase . During transition phase ( 21 day length ) , patient 's dose double-blind study drug gradually reduce stop treatment open-label RWJ-333369 start . Throughout remainder open label extension phase , investigator allow make adjustment dosage schedule carisbamate , include independent adjustment morning evening dos , dosage 1,200 mg/day may exceed increase dosage must increments 200 mg/day . Patients , judgment investigator , continue benefit treatment RWJ-333369 may continue receive drug follow clinic visit every 3 month RWJ 333369 available prescription program terminate sponsor . Initial dose RWJ-333369 1 capsule ( 250 milligram ( mg ) take twice daily . Dosage may change weekly interval . The maximum permit dose 4 capsule ( 1000 mg ) , twice daily dose titration . Double blind-treatment duration 71 day option continue treatment open-label study . Maximum dose open-label study 1200 mg/day</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<criteria>In order enter open label extension , patient must complete Study 333369EPY2001 . Patients seizure quantitated accurately patient history nonepileptic seizure , serious systemic disease , progressive neurologic disorder , major psychiatric disorder , status epilepticus past 3 month , vagal nerve stimulation discontinuation within past 3 month patient history drug alcohol abuse within past 2 year patient currently take felbamate , vigabatrin , tricyclic antidepressant female patient pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Refractory partial epilepsy</keyword>
	<keyword>seizure disorder</keyword>
	<keyword>antiepileptic drug</keyword>
</DOC>